Spectrum To Pay $206M For Cancer Drug Manufacturer
Spectrum said it had agreed to acquire the outstanding shares of Allos, which makes and markets the Folotyn cancer drug, for $1.82 per share plus one contingent value right.
The transaction is expected to close in the second quarter of 2012.
Spectrum Chairman, President and CEO Rajesh Shrotriya said in a statement that the company plans to leverage the...
To view the full article, register now.